Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 112

Results For "NAL"

6624 News Found

in-cosmetics Asia 2025 smashes records, draws global beauty elite
News | November 21, 2025

in-cosmetics Asia 2025 smashes records, draws global beauty elite

Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation


FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
Drug Approval | November 21, 2025

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options


Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension
Clinical Trials | November 21, 2025

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction


India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions
Healthcare | November 21, 2025

India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions

According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic


AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
Drug Approval | November 21, 2025

AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients

The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study


BPL Medical Technologies brings next-gen Korean ultrasound to India
Medical Device | November 21, 2025

BPL Medical Technologies brings next-gen Korean ultrasound to India

The X CUBE 50 integrates ALPINION’s advanced X+ Architecture


Merck’s two-drug HIV regimen hits phase 3 success
Clinical Trials | November 21, 2025

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks


Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
Drug Approval | November 21, 2025

Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment

This is the first and only subcutaneous immune checkpoint inhibitor available in Europe


Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs
R&D | November 21, 2025

Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs

Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure